U.S. secures GSK-Vir COVID-19 antibody therapy doses worth $1 billion

(Reuters) -The United States has signed contracts worth about $1 billion for doses of the antibody-based COVID-19 treatment from Britain’s GSK and U.S.-based Vir Biotechnology, as countries seek to secure promising options beyond vaccines.

FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera/File Photo

The drugmakers said on Wednesday the U.S. orders bring the total number of doses to be supplied to more than 750,000 globally, without specifying how many doses of the treatment, sotrovimab, the U.S. government had signed up for.

However, other public deals for the drug include 10,000 doses for Canada here and up to 220,000 doses for the European Union here. Values of those orders have not been disclosed.

U.S. deliveries of the treatment, branded Xevudy, are expected by Dec. 17 and the government will also have an option to buy more doses through March 2022, GSK and Vir said in their joint statement.

While vaccines remain at the heart of the long-term fight against the COVID-19 pandemic, treatments including game-changing antiviral pills from Merck and Pfizer, offer options to contain infections and save lives.

Pfizer said on Tuesday it was seeking U.S. authorisation of its experimental antiviral COVID-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial.

GSK-Vir’s sotrovimab has shown to reduce that risk by 79% in trials here.

Unlike oral options from Merck and Pfizer, sotrovimab is given via an infusion. It belongs to a class of medicines called monoclonal antibodies which are lab-generated compounds that mimic the body’s natural defences.

The therapy was authorised for emergency use here in the United States in May to prevent mild or moderate cases of COVID-19 from worsening. The European regulator has given its go-ahead for use by member states, although EU-wide approval is still pending.

“Given ongoing evidence, which demonstrates its ability to maintain activity against the tested circulating variants of concern, including Delta, we are confident sotrovimab will continue to be important,” Vir Chief Executive George Scangos said.

Last week, GSK and Vir said the antibody treatment was shown in a trial to work as well when given as a shot in the arm when administered via the standard infusion, potentially offering more convenience.

Sotrovimab brought in sales here of 130 million pounds ($175 million) for GSK in the first nine months of 2021.

Similar products are offered or being developed by Eli Lilly, Regeneron, AstraZeneca and Celltrion.

Last month U.S. authorities said the government would control distribution here of sotrovimab in the country.

($1 = 0.7427 pounds)

Source: Read Full Article